Fate Therapeutics (FATE) Receivables - Accured (2019 - 2026)

Fate Therapeutics (FATE) has 8 years of Receivables - Accured data on file, last reported at $800000.0 in Q1 2026.

• Quarterly Receivables - Accured fell 60.0% year-over-year to $800000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $800000.0 (down 60.0% YoY) and the FY2025 annual result came in at $700000.0, down 66.67% from the prior year.
• Receivables - Accured climbed to $800000.0 in Q1 2026, from $700000.0 in the prior quarter.
• In the past five years, Receivables - Accured ranged from a high of $2.1 million in Q4 2024 to a low of $1000.0 in Q2 2022.
• A 5-year average of $1.1 million and a median of $1.0 million in 2022 frame the typical range for Receivables - Accured.
• Annual changes were most pronounced in 2022 — Receivables - Accured tumbled 99.95% — and 2024, when it surged 154445.45%.
• Tracing FATE's Receivables - Accured over 5 years: stood at $800000.0 in 2022, then increased by 12.5% to $900000.0 in 2023, then soared by 133.33% to $2.1 million in 2024, then slumped by 66.67% to $700000.0 in 2025, then increased by 14.29% to $800000.0 in 2026.
• The last three Receivables - Accured figures came in at $800000.0 (Q1 2026), $700000.0 (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.